Retinal diseases such as age-related macular degeneration (AMD) and diabetic retinopathy affect millions of people globally, often leading to vision loss with minimal straightforward treatment.
An intravitreal ranibizumab injection was able to improve retinal sensitivity and thickness along with improving visual acuity. Branch retinal vein occlusion (BRVO) can affect people aged 40 years and ...
Clearside Biomedical Showcases Suprachoroidal Injection Platform for Retinal Diseases at CTS Meeting
Clearside Biomedical, Inc. has announced that its suprachoroidal injection delivery platform will be prominently featured at the Clinical Trials at the Summit (CTS) Meeting on June 21, 2025, in Las ...
Patients with neovascular age‑related macular degeneration (AMD) whose retinal fluid cleared within 12 weeks of starting faricimab were more likely to have longer intervals between injections later in ...
EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 ...
TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...
The demand for intravitreal vascular endothelial growth factor (VEGF) inhibitor therapy is forecasted to increase by about 50% over the next 5 years in Denmark, due largely to an aging population, a ...
Science has added a whole lot more cash to the bank, bringing in an impressive $230 million in its latest raise. | Science has added a whole lot more cash to the bank, bringing in an impressive $230 ...
Following a second injection at eight weeks, the patient maintained stable vision and remained dry at 12 weeks, allowing for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results